Trial · NCT06004050
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Investigator Global Assessment for Chronic Hand Eczema Score (IGA-CHE TS) at Week 16 | Week 16 | The IGA-CHE score ranges from 0 (clear) to 4 (severe). Treatment response is defined as a score of 0 or 1. |
| Secondary | Hand Eczema Severity Index (HECSI)-90 at Week 16 | Week 16 | Defined as at least a 90% improvement in HECSI score from baseline. |
| Secondary | HECSI-75 at Week 16 | Week 16 | Defined as at least a 75% improvement in HECSI score from baseline. |
| Secondary | Percentage Change in HECSI Score From Baseline to Week 16 | Baseline and Week 16 | HECSI score is used to rate the severity of hand eczema and ranges from 0 (lowest possible score) to 360 (highest possible score). |
| Secondary | Number of Participants With Reduction of Hand Eczema Symptom Diary (HESD) Itch Score by ≥4 Points From Baseline at Week 16 | Baseline and Week 16 | |
| Secondary | Number of Participants With Reduction of HESD Score by ≥4 Points From Baseline at Week 16 | Baseline and Week 16 | |
| Secondary | Number of Participants With Reduction of HESD Pain Score by ≥4 Points From Baseline at Week 16 | Baseline and Week 16 | |
| Secondary | Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16 | Baseline and Week 16 | |
| Secondary | Change in HESD Score From Baseline to Week 16 | Baseline and Week 16 | |
| Secondary | Change in HESD Itch Score From Baseline to Week 16 | Baseline and Week 16 | |
| Secondary | Change in HESD Pain Score From Baseline to Week 16 | Baseline and Week 16 | |
| Secondary | Change in Hand Eczema Impact Scale (HEIS) Score | Baseline and Week 16 | |
| Secondary | Change in HEIS Proximal Daily Activity Limitations (PDAL) Score | Baseline and Week 16 | |
| Secondary | Number of Participants With Reduction of DLQI Score of ≥4 Points From Baseline at Week 16 | Baseline and Week 16 | |
| Secondary | Number of Treatment-Emergent Adverse Events (AEs) | From baseline to Week 16 | |
| Secondary | Number of Treatment-Emergent AEs | From Week 16 to Week 54 | |
| Secondary | Area Under the Curve (AUC 0-12) | Day 1 and Day 8 post-dose | |
| Secondary | Maximum Serum Concentration (Cmax) | Day 1 and Day 8 (0-12 hours post-dose) | |
| Secondary | Time to Peak Drug Concentration (Tmax) | Day 1 and Day 8 (0-12 hours post-dose) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06004050/registered